CD19 and lymphoma: In response to antigen downregulation or loss manifested by CD19-negative relapses common in B-ALL and much less reported in lymphoma patients [105,106], the generation of multispecific CAR-T cells simultaneously targeting several antigens has become a prospective therapeutic strategy [107].